Plus de 40 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Overcoming the epigenetic and therapeutic barrier of EVI1-overexpressing cancers (EVI1inCancer)
Date du début: 1 juin 2016, Date de fin: 31 mai 2021,
Deregulation of the EVI1 oncogene is a key transforming event in the development of many malignancies, most prominently very high-risk acute myeloid leukemia (AML), ovarian, colon, breast, non-small cell lung cancer, and soft-tissue sarcoma. For decades, both EVI1 function and the mechanism underlying its deregulation have been poorly understood. The consequent lack of a targeted therapy against E...
Voir le projet
1
Participant partenaire
TERMINÉ
Breast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypes (B-CAST)
Date du début: 1 sept. 2015, Date de fin: 31 août 2020,
Breast tumours are heterogeneous, and result from the complex interplay of multiple lifestyle/environmental and genetic risk factors. Through the EU-funded COGS project, we have identified a large number of germline variants that influence the risk of breast cancer. In combination, these variants can identify women at wide ranges of genetic risk, even in the absence of family history of breast can...
Voir le projet
13
Participants partenaires
TERMINÉ
Computational Biophotonics for Endoscopic Cancer Diagnosis and Therapy (COMBIOSCOPY)
Date du début: 1 juil. 2015, Date de fin: 30 juin 2020,
Key challenges in endoscopic tumor diagnosis and therapy consist of the detection and discrimination of malignant tissue as well as the precise navigation of medical instruments. Currently, a low level of sensitivity and specificity in tumor detection and lack of global orientation lead to both over- and undertreatment, tumor recurrence, intra-operative complications, and high costs. The goal of t...
Voir le projet
3
Participants partenaires
TERMINÉ
Regulating the immune regulators: targeting adaptive immune control (REGiREG)
Date du début: 1 juil. 2015, Date de fin: 30 juin 2020,
The immune system with its complex interactions of cells and molecules needs a very tight and specific interplay of control elements to ensure the establishment and re-establishment of immune homeostasis after challenges. Regulatory T cells (Tregs) are key-players in this regulatory network. It is now well accepted that deficiency or dysfunction of Tregs causes various severe immune disorders due ...
Voir le projet
1
Participant partenaire
TERMINÉ
Dissection of tumor heterogeneity in vivo (CancerHetero)
Date du début: 1 juin 2015, Date de fin: 1 juin 2020,
It is now widely accepted that tumors are composed of heterogeneous population of cells, which contribute to many aspects of treatment resistance observed in clinic. Despite the acknowledgment of the tumor cell heterogeneity, little evidence was shown about complexity and dynamics of this heterogeneity in vivo, mainly because of lacking flexible genetic tools which allow sophisticated analysis in ...
Voir le projet
1
Participant partenaire
TERMINÉ
Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities. (HEP-CAR)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Hepatocellular carcinoma (HCC) is the most common liver malignancy, with an estimated 750,000 new cases and 695,000 deaths per year, rating third in incidence and mortality in the world. Whilst incidence and mortality for other cancers are declining, HCC represents an increasing public health problem in Europe with men having a higher incidence than women. Several liver diseases lead to HCC and be...
Voir le projet
9
Participants partenaires
TERMINÉ
Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood (CANCER-ID)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,
Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential to improve the development of personalized medicines for cancer patients. This is of particular importance when biopsies of the primary tumor or metastases are not accessible (e.g. at early disease stages or in minimal residual disease) or possible and the ass...
Voir le projet
34
Participants partenaires
TERMINÉ
Deciphering the machinery involved in stability of the transcription factor HOXA9. (HOXA9 degradome)
Date du début: 7 nov. 2016, Date de fin: 6 nov. 2019,
Transcription factors are often mutated or aberrantly expressed in cancer and drive carcinogenesis. HOXA9 is a master transcription factor that controls a network of genes critical for hematopoiesis. It shows increased expression levels in more than 50% of patients with acute myeloid leukemia (AML), and is strongly associated with poor clinical outcome. Since the initiation and progression of AML ...
Voir le projet
1
Participant partenaire
TERMINÉ
Coordinated Research Infrastructures Building Enduring Life-science services (CORBEL)
Date du début: 1 sept. 2015, Date de fin: 31 août 2019,
The social and economic challenges of ageing populations and chronic disease can only be met by translation of biomedical discoveries to new, innovative and cost effective treatments. The ESFRI Biological and Medical Research Infrastructures (BMS RI) underpin every step in this process; effectively joining scientific capabilities and shared services will transform the understanding of biological m...
Voir le projet
39
Participants partenaires
TERMINÉ
Ultra-low dose of IL-2 for the treatment of recently diagnosed type 1 diabetes (DIABIL-2)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2019,
ConceptThe discovery of regulatory T cells (Tregs) has revolutionized our understanding of autoimmune diseases. As T1D is caused by the failure of Tregs to block autoimmune destruction of pancreatic ß-cells, Treg stimulation has the potential to stop the process, preserve ß-cells’ insulin secretion, and likewise prevent or delay disease progression and improve clinical outcome for patients.Backgro...
Voir le projet
7
Participants partenaires
TERMINÉ
Towards outstanding research and training in tumour biology at IMM (ReTuBi)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2018,
Cancer is a major societal health issue in Europe. In 2012, cancer accounted for around 1.3 million deaths and an estimated economic impact of around € 126 billion in the European Union (EU).The Instituto de Medicina Molecular (IMM) aims to fight this destructive disease by reinforcing its capacity for outstanding pre-clinical and translation research, and by creating a dynamic cluster of excellen...
Voir le projet
3
Participants partenaires
TERMINÉ
European Regulatory Science on Tobacco:Policy implementation to reduce lung diseases (EUREST-PLUS)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2018,
Smoking and other forms of tobacco consumption are considered the single most important cause of preventable morbidity and premature mortality worldwide. Efforts to reduce the devastation of tobacco-related deaths and illness in the EU consist of the Tobacco Products Directive (TPD), and the ongoing implementation of the WHO Framework Convention on Tobacco Control (FCTC). The main objective of EUR...
Voir le projet
13
Participants partenaires
TERMINÉ
Development of Selective Carbohydrate Immunomodulators Targeting C-type Lectin Receptors on Antigen Presenting Cells (IMMUNOSHAPE)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
IMMUNOSHAPE aims at training a new generation of scientists that will be capable of combining state of the art synthesis and screening technology to develop new lead structures for highly selective glycan based multivalent immunotherapeutics for the treatment of cancer, autoimmune diseases and allergy. To this end, we have set up a training program in a unique academic-industrial environment that ...
Voir le projet
17
Participants partenaires
TERMINÉ
Epigenetic regulation of endocrine therapy resistance in breast cancer: A systems medicine approach to predict treatment outcome (EpiPredict)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
The mission of EpiPredict is to train a multidisciplinary cohort of young researchers in a new approach to fully exploit the epigenetics of complex diseases. The 12 early-stage researchers (ESRs) will focus on a narrowly defined case, Tamoxifen-induced resistance in Estrogen Receptor positive (ER+) breast cancer, considering five resistance interacting pathways. Given the frequent Tamoxifen treatm...
Voir le projet
8
Participants partenaires
TERMINÉ
Integrative Analysis of Gene Functions in Cellular and Animal Models of Pancreatic Cancer (CAM-PAC)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,
Cancers are genetic disease arising from the accumulation of multiple molecular alterations in affected cells. Large-scale genomic, transcriptomic and proteomic analyses have established comprehensive catalogues of molecules which are altered in their structure and/or abundance in malignant tumors as compared to healthy tissues. Far less developed are concepts and methods to integrate data from di...
Voir le projet
18
Participants partenaires
TERMINÉ
Validating predictive models of radiotherapy toxicity to improve quality-of-life and reduce side-effects in cancer survivors (REQUITE)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
Long-term side-effects of radiotherapy impact on the quality-of-life (QoL) of cancer survivors. These side-effects could be reduced if predicted in advance. Previous work identified clinical and biological predictors but a major, coordinated approach is needed to validate them so they can be used clinically. The EU has ~17.8 million people living with a prior diagnosis of cancer of whom ~7 million...
Voir le projet
15
Participants partenaires
TERMINÉ
implementAtion anD OPeration of the gateway for healTh into BBMRI-ERIC (ADOPT BBMRI-ERIC)
Date du début: 1 oct. 2015, Date de fin: 30 sept. 2018,
"BBMRI-ERIC: the Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium, aims to establish, operate and develop a Pan-European distributed research infrastructure in order to facilitate the access to biological resources as well as facilities and to support high quality biomolecular and biomedical research. The ADOPT BBMRI-ERIC proposal aims at ...
Voir le projet
22
Participants partenaires
TERMINÉ
Global Mapping of Synthetic Genetic Interactions in Drosophila (SYNGENE)
Date du début: 1 août 2012, Date de fin: 31 juil. 2018,
The genetics underlying phenotype-genotype relationships during development and disease is often complex with many genes contributing to a particular phenotypic outcome. While forward genetic screens have uncovered many mutations that are limiting at a particular stage or tissue, the majority of genes in most genomes remain genetically untouched. Recent studies in model organisms, in particular in...
Voir le projet
1
Participant partenaire
TERMINÉ
AusBildung wird Forschung - DKFZ-Auszubildende forschen europaweit
Date du début: 1 juil. 2016, Date de fin: 30 juin 2018,
In our 24 months project "AusBildung wird Forschung - DKFZ-Auszubildende forschen europaweit", the German Cancer Research Center will grant 32 apprentices the opportunity to partake in an internship as biological laboratory assistants, animal care takers, office clerks and qualified IT specialists. They will all finish the second year of training during the internship and they successfully complet...
Voir le projet
7
Participants partenaires
TERMINÉ
Gene Therapy for X-linked Chronic Granulomatous Disease (CGD) (NET4CGD)
Date du début: 1 déc. 2012, Date de fin: 31 mai 2018,
This project is focused on the clinical development of a new orphan drug that can rapidly become a new treatment option for patients with the X-linked form of chronic granulomatous disease (X-CGD). This rare primary immune deficiency of phagocytes is caused by mutations in the gp91phox gene. Affected patients are highly-susceptible to infections and develop inflammatory granulomas. Several member...
Voir le projet
11
Participants partenaires
TERMINÉ
Deciphering the regulatory T cell repertoire: towards biomarkers and biotherapies for autoimmune diseases (TRIPOD)
Date du début: 1 mai 2013, Date de fin: 30 avr. 2018,
The discovery of regulatory T cells (Tregs) is a breakthrough in immunology: it revolutionises our understanding of autoimmune disease (AID) pathophysiology and treatment opportunities. Treg numbers or function is defective in most mouse and human AIDs and their restoration induces clinical improvement, as we recently showed using low-dose IL-2 to induce Tregs in patients with AID.The TRiPoD proje...
Voir le projet
2
Participants partenaires
TERMINÉ
Mechanisms of Mismatch repair inactivation and identification of genes suppressing mutations (iMMR)
Date du début: 1 avr. 2014, Date de fin: 31 mars 2018,
The fidelity of DNA replication, and therefore the stability of the genome, relies on the DNA Mismatch repair (MMR) pathway, which recognizes DNA replication errors and promotes repair by an excision and re-synthesis mechanism. Mutations that inactivate MMR are associated to Lynch Syndrome, an early-onset cancer disorder characterized by accumulation of mutations at repetitive sequences or microsa...
Voir le projet
1
Participant partenaire
TERMINÉ
Defining the Impact of Chromosome Instability in Tumor Initiation, Maintenance and Relapse (MADCIN)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2018,
Chromosomal instability (CIN), the inability to correctly segregate sister chromatids during mitosis, is a hallmark of cancer cells. Overexpression of the mitotic checkpoint protein Mad2, commonly found in human tumors, leads to CIN and the development of aneuploid tumors in mouse models. However, recent observations from various laboratories suggest that aneuploidy can promote or suppress tumorig...
Voir le projet
2
Participants partenaires
TERMINÉ
PIVOTAL ASSESSMENT OF THE EFFECTS OF BIOACTIVES ON HEALTH AND WELLBEING. FROM HUMAN GENOMA TO FOOD INDUSTRY - PATHWAY (PATHWAY-27)
Date du début: 1 févr. 2013, Date de fin: 31 janv. 2018,
Scientific understanding of the role and mechanisms of bioactives is fragmented. Research often addresses the theoretical possibility of health improvement effects rather than their real, practical use for everyday diets. Bioactives cannot be considered as discrete chemical compounds and research must focus on bioactive-enriched foods (BEF), if consumer demands for foods delivering appropriate hea...
Voir le projet
28
Participants partenaires
TERMINÉ
Early warning signals of ageing in human stem cells and age-related disorders (SYSTEMAGE)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
The regenerative power of a living organism is linked to the potential of its stem cells to replace the corresponding damaged tissue. Therefore organisms are as old as their stem cells. Whereas the vulnerability to cancer and chronic inflammation is associated with a decline of the immune system, the latter is in turn a sum product of interactions among hematopoietic stem cells (HSC), endothelial ...
Voir le projet
11
Participants partenaires
TERMINÉ
Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action (EUROFANCOLEN)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
Fanconi anemia (FA) is a rare inherited syndrome characterized by the early development of bone marrow failure and increasing predisposition to cancer with age. Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for hematopoietic manifestations of FA, although associated with complications arising from myeloablation, graft versus host disease and increased inciden...
Voir le projet
13
Participants partenaires
TERMINÉ
Generating self-antigen diversity in the thymus: from gene expression patterns in single cells to the system level, an integrative approach (SELF-TOLERANCE)
Date du début: 1 juin 2012, Date de fin: 30 nov. 2017,
The thymus plays a central role in the induction of self-tolerance, a hallmark of the immune system. During T cell development a highly diverse T cell receptor repertoire is probed against a matching array of self-antigens. While the generation of the T cell receptor repertoire relies on unique genetic recombination mechanisms, the corresponding molecular principles underlying the generation of TC...
Voir le projet
1
Participant partenaire
TERMINÉ
Systems medicine of chronic inflammatory bowel disease (SYSMEDIBD)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2017,
Inflammatory bowel disease (IBD) is a major health problem with severe co-morbidities, requiring life-long treatment. Oscillating processes, like biological clocks are well studied and modeled in a number of systems. Circadian rhythms are extremely important for optimal treatments of patients. Recently, the NfkB pathway has been shown to be oscillating. In this project, we will model NfkB oscillat...
Voir le projet
13
Participants partenaires
TERMINÉ
Immunostimulatory Agonist antibodies for Cancer Therapy (IACT)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2017,
"This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system. The recent FDA-approval of Ipilimumab demonstrated that cancer immun...
Voir le projet
11
Participants partenaires
TERMINÉ
The impact of chromosomal instability on health: Molecular causes and consequences of aneuploidy (PLOIDYNET)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
Aneuploidy, an abnormal number of chromosomes, is a hallmark of cancer cells, affecting the majority of all human tumours. Aneuploidy arises when errors occur during mitosis, as the duplicated chromosomes are distributed between the two new daughter cells. Paradoxically, aneuploidy appears to have detrimental consequences for the physiology of untransformed cells in vitro, inhibiting rather than s...
Voir le projet
14
Participants partenaires
TERMINÉ
T-cell based immunotherapy in pancreatic cancer - basic concepts and pre-clinical development (TIPC_TIL_IP)
Date du début: 1 sept. 2013, Date de fin: 31 août 2017,
"Pancreatic ductal adenocarcinoma (PDA) has a devastating prognosis and novel treatment approaches are urgently needed. T cell-based immunotherapy making use of in vitro expanded tumor-infiltrating lymphocytes (TIL) has recently emerged as a potent therapy in melanoma, with the potential to cure even patients with advanced disease.We are currently working towards the development of TIL therapy for...
Voir le projet
1
Participant partenaire
TERMINÉ
Quantitative T cell Immunology (QuanTI)
Date du début: 1 mai 2013, Date de fin: 30 avr. 2017,
The primary objective of this ITN is to train a new generation of European quantitative immunologists, who will be able to address challenges arising in Systems Immunology. This will be achieved with the proposed Network, Quantitative T cell Immunology (QuanTI), that will train 11 ESRs and 4 ERs, bringing together renowned experimental and theoretical scientists from private and academic instituti...
Voir le projet
12
Participants partenaires
TERMINÉ
Unlocking the potential of ultra-high-field MRI through manipulation of radiofrequency excitation fields in human tissue (MRexcite)
Date du début: 1 mai 2012, Date de fin: 30 avr. 2017,
In the past three decades, magnetic resonance imaging (MRI) has become a vital tool for clinical diagnosis and research. A major current trend is the introduction of magnets with much more powerful static magnetic fields, including magnets at 7 Tesla (7T) and higher. Advantages of higher magnetic fields include higher signal-to-noise ratios enabling improved spatial and temporal resolution, and ne...
Voir le projet
2
Participants partenaires
TERMINÉ
Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI)
Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,
The current test systems employed by Industry are poorly predictive for Drug induced liver injury (DILI). The ‘MIP-DILI’ project will address this situation by the development of innovative preclinical test systems which are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative, tiered approach with respect to test compounds, test sys...
Voir le projet
29
Participants partenaires
TERMINÉ
A European Platform for Translational Cancer Research (EUROCANPLATFORM)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2016,
Europe has a number of advantages as regards developing translational cancer research, yet there is no clear European strategy to meet the increasing burden posed by cancer. The FP6 Eurocan+Plus project analysed the barriers underlying the increasing fragmentation of cancer research and stressed the need to improve collaboration between basic/preclinical and comprehensive cancer centres (CCCs), in...
Voir le projet
29
Participants partenaires
TERMINÉ
The RANK-Axis in Breast Cancer: A comprehensive prospective evaluation of promising novel biomarkers (RANKL_OPG)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2016,
"Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer mortality in women worldwide. The recently identified Receptor Activator of Nuclear Factor (NF)-κB (RANK)-axis has stimulated novel research in the field of breast cancer etiology, treatment, and prevention. Experimental data implicate RANK signalling in mammary tumor development. Preliminary human data show inc...
Voir le projet
1
Participant partenaire
TERMINÉ
Towards clinical translation of new gene targeting technologies for correcting inherited mutations and empowering adoptive immunotherapy of cancer (SUPERSIST)
Date du début: 1 mai 2013, Date de fin: 31 oct. 2016,
Substantial evidence supports the therapeutic potential of ex vivo gene therapy based on Hematopoietic Stem Cell (HSC) or T lymphocytes to treat inherited diseases or cancer. Yet, the intrinsic limitations of current gene replacement approaches based on semi-randomly integrating vectors, and the occurrence in some clinical trials of severe adverse events related to gene transfer, prevent safe depl...
Voir le projet
5
Participants partenaires
TERMINÉ
Identifying and characterising transmembrane transporters of tryptophan and kynurenine in normal and cancerous brain tissue (KP Transport)
Date du début: 1 sept. 2014, Date de fin: 31 août 2016,
The catabolism of the essential amino acid tryptophan (Trp) by tumour cells expressing either IDO1/2 or TDO has been associated with malignant tumour progression and poor patient survival. Expression of these rate-limiting genes leads to both depletion of Trp and accumulation of the Trp breakdown product kynurenine (Kyn) in the tumour microenvironment. Kyn has recently been shown to act as a lig...
Voir le projet
1
Participant partenaire
TERMINÉ
AusBildung wird Forschung - DKFZ-Auszubildende forschen europaweit
Date du début: 1 juil. 2014, Date de fin: 30 juin 2016,
In our 24 months project "AusBildung wird Forschung - DKFZ-Auszubildende forschen europaweit", 21 apprentices, 1 animal keeper who completed his training in 2015 and 3 staff members of the training department had the opportunity to partake. Most of the participants are completing an apprenticeship as biological laboratory assistants (17), office clerks (3) and qualified IT specialists (1). They al...
Voir le projet
7
Participants partenaires
TERMINÉ
ASSET: Analysing and Striking the Sensitivities of Embryonal Tumours (ASSET)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,
Cancer is hallmarked by multiple genetic aberrations that lead to a functional derangement of cellular signalling networks. Embryonal tumours (ETs) comprising neuroblastoma, medulloblastoma and Ewing sarcoma, occur early in life, and thus may reveal pathogenetically relevant lesions clearer than adulthood tumours which carry passenger mutations accumulated during life. ASSET will exploit this fact...
Voir le projet